Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

There was some good news in the clinical sphere for Gilead Sciences ( GILD 2.74%) on Thursday, and this drove its stock price ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

NORTHAMPTON, MA / ACCESSWIRE / September 18, 2024 / Gilead SciencesJackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the directio ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...